Guillen was named president and director in April, replacing Phil Passy, MedX’s founder, who passed away earlier in 2008.
Prior to joining MedX, Mr Guillen was CEO of Oxis International, where he was recruited to lead, and turn around, an asset-rich publicly traded company with products in diagnostics, therapeutics, and nutraceuticals.
Mr Guillen said: “We plan to build upon our success in bringing relief of symptoms in a non-pharmacologic manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as well as developing and commercializing advanced products in the dental and wound-care markets that will position us to increase revenue in new markets.”